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Background: Injection of dermal ﬁllers is one of the most commonly performed procedures in the cosmetic dermatology practice. As
its usage is expanding, the possibility of complications will likely increase.
Objective: To review and summarize the complications associated with hyaluronic acid injections, and to provide a guide to avoiding
them and managing these complications if they do occur.
Methods: A comprehensive PubMed and Google scholar electronic database search was performed (2005–July 2015). A total of ﬁfty-
ﬁve articles were selected and included.
Results: Most of the complications associated with hyaluronic acid ﬁller use are mild, transient and reversible. Serious complications
due to vascular occlusion include cutaneous necrosis and blindness, which although rare can occur due to the compression of the vessel
or direct intravascular injection.
Conclusion: Injection related side eﬀects are the most commonly seen, which are usually transient. Vascular occlusion is the most sev-
ere complication associated with hyaluronic acid ﬁller injection. A thorough understanding of the facial vascular anatomy reduces the
risk of vascular occlusion. Early identiﬁcation of a vascular occlusion and a prompt intervention can signiﬁcantly decrease the risk of
long term sequelae. Guidelines to avoid, identify and manage diﬀerent hyaluronic acid ﬁller complications have been suggested.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Injection of dermal ﬁllers is one of the most commonly
performed procedures in cosmetic dermatology practice.
According to recent data published by the American Soci-
ety of Plastic Surgeons (ASPS) in 2014, soft tissue ﬁller
injections increased by 253% since the year 2000 with 3%
increase from the year 2013 (2.3 million). Hyaluronic acid
(HA) ﬁllers constituted 78.3% of all injectable dermal ﬁllers
with 7.5% increase from the previous year (American
Society of Plastic Surgeons, 2014). Compatibility of HA
with the human body and reversibility of injected HA using
intralesional hyaluronidase enzyme make HA based der-
mal ﬁllers favorable for many injectors.
As the usage of dermal ﬁllers is expanding, complica-
tions will likely increase. Even in the hands of an experi-
enced injector, various complications can occur.
Fortunately, most of the complications associated with
HA ﬁllers are mild, transient and reversible.
Injection technique related adverse eﬀects are the most
commonly seen. Maximizing injection technique and thor-
ough understanding of potential complications and their
management can help avoid, identify and manage them
when they do occur.2. Hyaluronic acid ﬁllers
HA forms an integral part of the natural extracellular
matrix which is found in high amounts in several connec-
tive tissues including the skin, the vitreous humor of the
eye and the synovial ﬂuid (Stern and Maibach, 2008).
Chemically, HA is a linear polysaccharide composed of
repeating disaccharide units of glucuronic acid and N-
acetylglucosamine (Sudha and Rose, 2014). HA is consid-
ered to be the most popular dermal ﬁller to replace volume
loss due to normal aging for several reasons including: its
hygroscopic property, biocompatibility and reversibility.
Over the past several decades, various forms of HA ﬁllers
have been developed and they diﬀer in many aspects
including: the type and degree of crosslinking, gel viscosity,
gel hardness, gel consistency, extrusion force, total HA
concentration and duration of presence in the skin (Tezel
and Fredrickson, 2008). Diﬀerent FDA HA ﬁller products
are shown in (Table 1).3. HA ﬁllers complications
HA ﬁller complications can be divided into early and
delayed onset complications according to the time of
appearance of symptoms and signs. Early onset complica-
tions typically appear hours to days post procedure while
delayed onset complications usually develop weeks to years
post HA ﬁller injection (Table 2).
4. Injection site adverse eﬀects
The most common side eﬀects associated with HA injec-
tion are local injection related side eﬀects which manifest as
edema, pain, erythema, itching and ecchymosis (Lafaille
and Benedetto, 2010). These adverse side eﬀects are mild
and usually last less than one week.
Pain is considered to be a common adverse eﬀect during
HA injection. Several techniques can be used in order to
minimize the pain associated with injections, which
include: the utilization of the small needle gauge or
blunt-tipped cannulas, the use of topical anesthetic agents,
application of ice prior and after injection, vibratory dis-
traction and nerve blocks (Jean Carruthers, 2013).
Ecchymosis and edema can be minimized by stopping
the intake of aspirin, NSAID, supplements containing
ginkgo biloba, vitamin E, omeg-3, ﬁsh oil, ginseng, kava–
kava and St John’s wort at least one week prior to the pro-
cedure (Gilbert et al., 2012). Before and after procedure use
of arnica, topical vitamin K or bromelin may decrease the
post-injection ecchymosis, but no controlled studies prove
their eﬀectiveness (Jones, 2010). Some practitioners use
the vascular laser to reduce post-injection bruises (Jean
Carruthers, 2013).
The Tyndall eﬀect is caused by placing the HA ﬁllers too
superﬁcially and it manifests as bluish discoloration, which
can be treated by injecting 15–50 IU of hyaluronidase fol-
lowed by massage (DeLorenzi, 2013).
5. Hypersensitivity reactions
Safety data on non-animal-derived hyaluronic acid
(NASHA) gel show that it has a favorable safety proﬁle.
One study on the use of NASHA found that localized
hypersensitivity, which was deﬁned as ‘‘swelling, erythema,
Table 1
U.S FDA* approved HA ﬁllers.
Product Active content Manufacturer Date of
approval
Approved indications for usage
RESTYLANE
INJECTABLE GEL
Hyaluronic acid Q-med Ab 2003 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles and folds (such as
nasolabial folds)
HYLAFORM (HYLAN
B GEL)
Modiﬁed hyaluronic
acid derived from a bird
(avian) source
Genzyme Biosurgery 2004 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles and folds (such as
nasolabial folds)
CAPTIQUE
INJECTABLE GEL
Hyaluronic acid Genzyme Biosurgery 2004 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles and folds (such as
nasolabial folds)
RESTYLANE
INJECTABLE GEL
Hyaluronic Acid Medicis Aesthetics
Holdings, Inc
2005 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles and folds (such as
nasolabial folds)
JUVEDERM 24HV,
JUVEDERM 30, and
JUVEDERM 30HV
Hyaluronic Acid Allergan 2006 Use in mid to deep dermis for correction of moderate to
severe facial wrinkles and folds (such as nasolabial folds)
ELEVESS Hyaluronic Acid with
Lidocaine
Anika Therapeutics 2006 Use in mid to deep dermis for correction of moderate to
severe facial wrinkles and folds (such as nasolabial folds)
PREVELLE SILK Hyaluronic Acid with
Lidocaine
Genzyme Biosurgery 2008 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles and folds (such as
nasolabial folds)
RESTYLANE
INJECTABLE GEL
Hyaluronic Acid Medicis Aesthetics
Holdings, Inc
2011 Lip augmentation in those over the age of 21 years
BELOTERO BALANCE Hyaluronic Acid with
Lidocaine
Merz Pharmaceuticals 2011 Injection into facial tissue to smooth wrinkles and folds,
especially around the nose and mouth (nasolabial folds)
RESTYLANE-L
INJECTABLE GEL
Hyaluronic Acid with
Lidocaine
Medicis Aesthetics
Holdings, Inc.
2012 Injection into the mid to deep dermis for correction of
moderate to severe facial wrinkles/folds (such as
nasolabial folds) and for lip augmentation in those over
the age of 21 years
JUVEDERM
VOLUMNA XC
Hyaluronic Acid with
Lidocaine
Allergan 2013 Indicated for deep (subcutaneous and/or supraperiosteal)
injection for cheek augmentation to correct age-related
volume deﬁcit in the mid-face in adults over the age of 21
RESTYLANE SILK Hyaluronic Acid with
Lidocaine
Valeant
Pharmaceuticals
North America LLC/
Medicis
2014 Indicated for lip augmentation and dermal implantation
for correction of perioral rhytids (wrinkles around the
lips) in patients over the age of 21
* United States Food and Drug Administration.
Table 2
Classiﬁcation of HA ﬁllers complications.
Early onset adverse eﬀects
(Hours to days post procedure)
Delayed onset adverse eﬀects
(weeks to years post procedure)
Injection site reaction Bioﬁlms
Edema Foreign body granuloma
Pain Dyspigmentation
Erythema Scarring
Itching
Ecchymosis
Hypersensitivity reaction
Infection
Herpes simplex virus infection
Abscess/cellulitis
Mycobacterial infection
Tyndall eﬀect
Surface irregularities and nodules
Vascular occlusion
Local tissue necrosis
Embolization of blood vessels
(blindness, stroke)
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in the surrounding tissue with a median duration of
15 days”, occurred in only 1 of every 1400 patients.
Another study found only a 0.8% incidence of acute or
delayed hypersensitivity reactions to NASHA gel
(Leonhardt et al., 2005).
NASHA may contain immunogenic protein, potentially
introduced through the manufacturing process. Hypersen-
sitivity reactions to Restylane (Medicis Aesthetics Inc.)
documented in the 1990 s are believed to have been related
to protein contaminants. The reduction in the frequency of
hypersensitivity reactions since the year 2000 may be partly
explained by the introduction of a hyaluronic raw material
with trace amounts of protein six times lower than the raw
material previously used (Van Dyke et al., 2010).
Leonhardt et al. (2005) reported a case of angioedema
hypersensitivity reaction following the injection of Resty-
lane in the upper lip. This patient, however, was treated
with a systemic corticosteroid.
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Injectable ﬁllers are also associated with infections,
which can result from the breach in skin surface integrity.
The infectious agents may be bacterial, viral or fungal. In
order to minimize the risk of infection, the patients’ history
should be taken, including any history of recent dental pro-
cedures, any periodontal treatment planned within the next
two weeks or any history of chronic sinusitis. The patient
should not wear makeup either before or immediately after
the procedure. Aseptic technique should be used, including
proper skin sterilization with 2–4% chlorhexidine or 70%
isopropyl alcohol solution and avoiding contamination of
the treatment area after cleansing the patient’s skin. An
injection approach should be used that reduces the number
of skin piercings and uses the smallest gauge needle possi-
ble for injections. It is also important to avoid injecting
into inﬂamed or infected skin, to avoid intraoral injections
and to avoid injecting through previous layers of ﬁller
(Bailey et al., 2011; Ozturk et al., 2013; Cox and Adigun,
2011).
7. Herpes simplex infection
Reactivation of herpes simplex infection, especially
when performing lip augmentation, is not an uncommon
adverse eﬀect and should be addressed properly. Patients
with a history of recurrent herpes simplex outbreaks should
receive prophylactic antiviral therapy in the form of valacy-
clovir 500 mg bid 2 days before the procedure and 3 days
after. Patients with active lesions of herpes simplex infec-
tion should postpone their procedure. Patients who
develop new lesions post injection need to be started on
an appropriate antiviral regimen and appropriate oral
antibiotic if a superadded bacterial infection develops
(Funt and Pavicic, 2013; Sanchez-Carpintero et al., 2010).
8. Abscess and cellulitis
Bacterial inoculations can occur after ﬁller injections as
a result of skin surface breakage.(Daines and Williams,
2013) Inﬂammatory nodules that present with erythema,
edema and tenderness, in other words, a ‘‘red angry
bump”, which presents within 3–14 days should be treated
as an infection. The patient should be examined for ﬂuctu-
ance, and if ﬂuctuance is noticed, incision and drainage are
needed. Although staphylococci and streptococci bacteria
are the most commonly identiﬁed organisms, the expressed
material should be sent for broad culture for 10–21 days
(under aerobic and anaerobic growth conditions). Another
approach is to aspirate the lesion with an 18-gauge needle
after applying topical anesthesia. The patient should be
started on empiric broad-spectrum antibiotics immediately,
selecting drugs that provide coverage against acid-fast
bacilli, atypical mycobacteria, and MRSA, such as macro-
lide and tetracycline (clarithromycin 500 mg and minocy-
cline 100 mg twice daily for 4–6 weeks). If there is noresponse after 48-h of follow up, take a 2 mm punch biopsy
for tissue culture and adjust the antibiotics accordingly.
Hyaluronidase can also be used to dissolve the nidus of
the infection. In the case of severe infection, an immuno-
compromised patient, or infection in facial danger zones,
hospitalization is warranted and intravenous antibiotics
must be started (Funt and Pavicic, 2013; Narins et al.,
2009; Levy and Emer, 2012; Sclafani and Fagien, 2009).
9. Mycobacteria
Post ﬁller bacterial infection with Mycobacterium
abscessus was reported in New York City in 2002 after a
non-FDA approved HA ﬁller was used (Hyacell) which
was illegally imported from South America (Rousso and
Pitman, 2010; Cohen, 2008). Rodriguez et al. (2013)
reported three cases of Mycobacterium chelonae infection
after a dermal ﬁller injection that was isolated from clinic
tap water (Rodriguez et al., 2013).
10. Bioﬁlms
A bioﬁlm is a collection of bacteria surrounded by a
protective and adhesive matrix, which was ﬁrst discovered
on dental plaques (DeLorenzi, 2013; Kunjur and
Witherow, 2013). Bioﬁlms use the implanted ﬁller as a sur-
face on which to attach and excrete their own matrix. This
matrix gives them the ability to survive, develop and resist
antibiotic treatment up to a thousand times more eﬀec-
tively than planktonic bacteria. This excreted polymeric
material entraps leukocytes and prevents phagocytosis
(Cassuto and Sundaram, 2013; Marusza et al., 2012).
These microorganisms develop DNA mutations and
achieve subsequent diversity (Narins et al., 2009). These
bacterial colonies become active when conditions are favor-
able, for instance after trauma and manipulation. They can
cause a variety of clinical presentations including cellulitis,
abscesses, nodules or granulomatous inﬂammation, which
can manifest weeks, months or even years after dermal ﬁl-
ler injections (Cassuto and Sundaram, 2013).
The current mechanisms for culture have not success-
fully identiﬁed the causative bacteria. Diagnosis can be
conﬁrmed using PCR of bacterial protein or ﬂuorescence
in situ hybridization (Cassuto et al., 2009). Empiric antibi-
otics should be started while waiting for the PCR results;
two or three antibiotic therapies would be appropriate,
and macrolide and quinolone have been recommended,
with clarithromycin 500 mg bid and ciproﬂoxacin 500 mg
bid for 4–6 weeks (Funt and Pavicic, 2013; Constantine
et al., 2014). Hyaluronidase can help cleave and fragment
the enclosing matrix, hence reducing the amount of bioﬁlm
and helping the antibiotics work (Ozturk et al., 2013).
11. Foreign body granuloma
Foreign body granuloma is a chronic inﬂammatory
reaction that entraps a foreign body, preventing its
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the immune system to enzymatically degrade or phagocy-
tose the foreign body (Funt and Pavicic, 2013).
The pathogenesis of these granulomatous responses
remains unknown. HA ﬁllers may still contain little
amounts of protein contaminants after puriﬁcation, which
can carry a risk for hypersensitivity reactions and granu-
loma formations. On the other hand, cross-linking stabi-
lizes HA ﬁller and prevents its degradation, as cross-
linking is breaking down, the components used to stabilize
the HA ﬁller may induce an immunologic reaction
(Mamelak et al., 2009; Alsaad et al., 2012). The incidence
of foreign body granuloma after the injection of HA ﬁllers
ranges from 0.02% to 0.4% (Lemperle et al., 2009; Lee and
Kim, 2015).
Granulomatous reactions generally have a delayed onset
after ﬁller injections, appearing as red papules, plaques or
nodules with a ﬁrm consistency which may result from
ﬁbrosis in late stages; if ﬂuctuance is present, an infectious
etiology must be ruled out (Lemperle et al., 2009). True
granuloma must be conﬁrmed histologically, by the pres-
ence of multinucleated giant cells that surround the baso-
philic product (Daines and Williams, 2013).
Intralesional hyaluronidase is an eﬀective therapy for
granulomatous lesions secondary to HA ﬁller (Brody,
2005; Rzany et al., 2009; Curi et al., 2015). Alsaad et al.
reported a case series of three patients who developed gran-
ulomatous reaction to HA ﬁller three moths post proce-
dure. All patients were injected with Prevelle Silk for
periocular and perioral rhytides. Hyaluronidase was
injected into the granulomatous nodules with a complete
resolution of the skin lesions (Alsaad et al., 2012). Other
treatments that can be used to resolve granulomas include
systematic and intralesional corticosteroids, systemic oral
antibiotics, intralesional5-ﬂuorouracil and laser treatment
(Cox and Adigun, 2011; Funt and Pavicic, 2013; Curi
et al., 2015; Lemperle and Gauthier-Hazan, 2009; Park
et al., 2011).
12. Vascular occlusion
Vascular occlusion is the most concerning complication
regarding ﬁller injections. It can be a localized occlusion,
resulting in skin necrosis, or a distant occlusion causing
blindness or cerebral ischemic events (Carle et al., 2015;
DeLorenzi, 2014). Localized vascular occlusion results
from either direct intravascular injection or the compres-
sion of the vessels by the injected ﬁller material (Cox and
Adigun, 2011).
Arterial occlusion due to intra-arterial injection usually
presents with an immediate or early skin blanching and
varying degrees of pain; if not treated swiftly, the aﬀected
skin will develop reticulated erythema, purpura and ulcer-
ation and consequently, scarring (Gilbert et al., 2012).
Delayed onset arterial occlusion secondary to external
compression by the injected ﬁller can also occur (Hirsch
et al., 2007).Venous occlusion occurs either by accidental intra-
venous injection or by placing a large amount of the ﬁller
material in a small area leading to venous compression
(DeLorenzi, 2014; Kassir et al., 2011). It has a more
delayed presentation with persistent, dull aching pain, swel-
ling and violaceous reticulated erythema of the skin
(Sclafani and Fagien, 2009). These features can be misinter-
preted as injection induced bruising, pain and swelling, but
the severity and the persistence of the pain should alert the
physician to the possibility of vascular occlusion (Gilbert
et al., 2012).
Blindness is the most feared complication of ﬁllers injec-
tion. It has been proposed that accidental high injection
pressure of the supratrochlear, supraorbital, angular and
dorsal nasal arteries which are branches of the external car-
otid artery will result in a retrograde ﬂow of the ﬁller
emboli into the ophthalmic artery (Carle et al., 2015). Once
the physician stops the pressure on the plunger, the arterial
pressure will push the ﬁller emboli into the retinal circula-
tion resulting in the loss of vision (Carruthers et al., 2014).
If the physician applies a greater force for a long time, the
ﬁller emboli can reach the internal carotid artery and then
be propelled into the intracranial circulation resulting in
cerebral ischemic events (Carle et al., 2015; Kim et al.,
2014).
The main high risk facial zones for skin necrosis and
embolization are the glabella, nasal ala and dorsum of
the nose (Bray et al., 2010). Several measures can be taken
to minimize the risk of vascular complications including:
through understanding of the facial anatomy, aspiration
before each injection, low pressure injections of minimal
volumes (<0.1 ml/injection), dilution of the ﬁller with lido-
caine and/or epinephrine, keeping the needle moving
(bolus injections should be given only in the periosteum
plane), avoid injections in areas of previous scarring and
use of blunt cannulas, which may reduce the risk of
intravascular placement of the ﬁller material (Funt and
Pavicic, 2013; Levy and Emer, 2012; Cohen, 2008;
DeLorenzi, 2014; Glaich et al., 2006).
If features of tissue necrosis appear, the injection should
be stopped, and an immediate injection of hyaluronidase
enzyme is crucial in order to minimize the amount of tissue
necrosis (Beer et al., 2012). This enzyme acts by hydrolyz-
ing HA by splitting the glucosaminidic bond between C1 of
the glucosamine moiety and C4 of the glucuronic acid
(Kassir et al., 2011). Several formulations of hyaluronidase
can be used which include amphadase (derived from bovine
testicular hyaluronidase), vitrase (derived from ovine hya-
luronidase) and hylenex (a recombinant human hyaluroni-
dase) (Rzany et al., 2009).
Although rarely done in clinical practice, especially in
urgent situations such as impending tissue necrosis, prelim-
inary skin testing is recommended for vitrase and ampha-
dase because of their animal origin (Gilbert et al., 2012).
Inject a signiﬁcant amount of hyaluronidase (200 units)
which can be diluted either with lidocaine to induce vasodi-
latation and HA dispersion or with saline to allow coverage
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60 min, an extra volume of hyaluronidase can be injected
again (repeat up to 4 cycles) (Cohen et al., 2015).
The adverse events of hyaluronidase are uncommon,
with injection related side eﬀects being the most commonly
reported (Hirsch et al., 2007). Less than 0.1% of patients
injected with hyaluronidase develop urticaria and angioe-
dema but there are no reported cases of anaphylaxis after
subepidermal injections (Lee et al., 2010). Be cautious when
using hyaluronidase in patients with a history of bee allergy
because hyaluronidase is considered to be one of the active
components in bee venom (Gilbert et al., 2012).
Moreover, the application of warm compresses (for 5–
10 min every 1–2 h) and vigorous massage are important
to stimulate vasodilatation and disburse the bulk of the ﬁl-
ler material respectively (Sclafani and Fagien, 2009; Beer
et al., 2012). Additionally, apply a half inch of 2% nitro-
glycerin paste daily to the aﬀected area to stimulate further
vasodilatation (Dayan et al., 2011). Start the patient on 2
pills of 325 mg of aspirin daily for a week to prevent the
further clot formation in association with antacid to avoid
gastritis (Hirsch et al., 2007).
The patient should be followed up daily for clinical
improvement or worsening. If the condition worsens, hya-
luronidase, aspirin and NTG paste must be repeated daily
for additional two to three days (Cohen et al., 2015).
If necrosis is progressive and not responsive to the above
treatments, consider hyperbaric oxygen therapy (Dayan,
2013). Of note, topical oxygen therapy, low molecular
weight heparin, systemic steroids, sildenaﬁl, platelet-rich
plasma ﬁller removal through puncture and intravenous
prostaglandin are reported to be of beneﬁcial (Daines
and Williams, 2013; Kim et al., 2014; Kang et al., 2015;
Beleznay et al., 2014).
Proper wound care is important in order to minimize the
risk of scarring.
In the case of vision loss or ocular pain, stop injection
immediately and contact an ophthalmologist or an oculo-
plastic surgeon for urgent retrobulbar injection of hyaluro-
nidase which can dissolve intravascular as well as
extravascular hyaluronic acid (Carruthers et al., 2014).
13. In conclusion
HA ﬁllers are the predominantly used dermal ﬁllers
worldwide. Luckily, most complications associated with
HA ﬁller injection are mild and self-limiting. The rare vas-
cular and infectious complications associated with HA ﬁl-
ler injection can be minimized with a thorough
understanding of facial vascular anatomy, proper injection
techniques and meticulous skin preparation. Early identiﬁ-
cation and a prompt intervention can signiﬁcantly decrease
the risk of long-term sequelae.
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